メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
岡本 晃直
血液内科学
h-index
564
被引用数
14
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2012
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(44)
類似のプロファイル
(6)
フィンガープリント
Akinao Okamotoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Induction Chemotherapy
57%
D-index
55%
Febrile Neutropenia
50%
Flow Cytometric
50%
NUP98-HOXA9
50%
In Vitro Anticancer Activity
50%
DEK-NUP214
50%
Solanum Torvum Swartz
50%
COL12A1
50%
Chromosome 9
50%
NUP214
50%
Variant Translocation
50%
Complex Variants
50%
Methyl Caffeate
50%
Diagnostic Specimen
50%
Streptomyces Olivochromogenes
50%
Circulating Tumor DNA (ctDNA)
50%
Antimicrobial Properties
50%
Spinal Cord
50%
Epstein-Barr Virus-positive mucocutaneous Ulcer
50%
Upper Part
50%
DNA Detection
50%
Serum IgG Level
50%
Relapsed Lymphoma
50%
CBDCA
50%
R-CHOP Therapy
50%
Combination of Therapies
50%
System Restoration
50%
9,10-anthraquinone
50%
Severe Hepatitis
50%
CHOP Chemotherapy
50%
Rituximab-CHOP
50%
COVID-19 mRNA Vaccination
50%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
50%
COX-2 Inhibition
50%
Subgroup Analysis
50%
Cerebrospinal Fluid
50%
VPS13B
50%
Cohen Syndrome
50%
Antifungal Therapy
50%
Hematology
50%
Biomarker Monitoring
50%
Fungal Biomarkers
50%
Invasive Fungal Disease
50%
Bystander Cells
50%
Micafungin
50%
COVID-19 Disease
50%
Mannich Derivatives
50%
Anticancer Properties
50%
Varicella Outbreak
50%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Febrile Neutropenia
100%
Dexamethasone
100%
Antiproliferative Activity
83%
Cytochrome C
64%
Caspase
57%
Ifosfamide
50%
Carboplatin
50%
B Cell Lymphoma
50%
Antifungal Therapy
50%
Biological Marker
50%
Disease
50%
Caffeic Acid
50%
Bortezomib
50%
Solanum Torvum
50%
Burkitt's Lymphoma
50%
Janus Kinase
50%
Bloodstream Infection
50%
Mycosis
50%
Multiple Myeloma
50%
Combination Therapy
50%
Anthraquinone
50%
Immunocompromised Patient
50%
Clinical Study
50%
Nonhodgkin Lymphoma
50%
Etoposide
50%
Circulating Tumor DNA
50%
Tumor Lysis Syndrome
50%
Lenalidomide
50%
Micafungin
50%
Chemotherapy
43%
Immune Deficiency
37%
Peripheral Neuropathy
33%
Caspase 3
30%
Malignant Neoplasm
23%
Adverse Event
21%
Acetic Acid Ethyl Ester
21%
Galactomannan
20%
Glucan
20%
Colorectal Cancer
18%
Hematologic Malignancy
18%
Antiinfective Agent
18%
Herpes Zoster
16%
Mouse Model
16%
Tumor Growth
16%
Liver Cell Carcinoma
16%
Antitumor Activity
16%
Chemotherapy Regimens
16%
Cytochrome C3
16%
Hexane
14%
Medicine and Dentistry
Febrile Neutropenia
100%
Induction Chemotherapy
57%
Hematology
55%
Bortezomib
50%
Clinical Study
50%
COVID-19
50%
Dexamethasone
50%
Tumor Lysis Syndrome
50%
Acute Myeloid Leukemia
50%
Circulating Tumor DNA
50%
Bloodstream Infection
50%
Post-Hoc Analysis
50%
Factor Analysis
50%
Immunocompromised Patient
50%
Transplantation
50%
Antifungal Therapy
50%
Magnetic Resonance Imaging
50%
Disease Burden
50%
Subgroup Analysis
50%
Cerebrospinal Fluid
50%
Multiple Myeloma
50%
Lenalidomide
50%
Micafungin
50%
Chickenpox
50%
B-Cell Lymphoma
50%
Rituximab
50%
Immune Deficiency
41%
Disease
35%
Peripheral Neuropathy
33%
Population
25%
Immune Function
25%
Group Therapy
21%
Hematologic Malignancy
18%
Antiinfective Agent
18%
Chemotherapy Regimens
16%
Adverse Event
16%
Disseminated Herpes Zoster
16%
Drug Therapy
12%
Malignant Neoplasm
12%
Clinical Trial
12%
Solid Organ Transplantation
12%
Rheumatic Disease
12%
COVID-19 Vaccine
12%
Blood Culture
12%
Nephropathy
12%
Human Immunodeficiency Virus
12%
Infection
12%
Antibody Response
12%
Supportive Care
12%
Immunosenescence
11%
